Gwajin asibiti da FDA ta amince da ita don cutar kansar kwakwalwa ta glioblastoma

A KYAUTA Kyauta 5 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Kairos Pharma, Ltd., wani kamfani mai zaman kansa mai zaman kansa na masana'antar fasahar kere-kere da ke mayar da hankali kan juriya na magunguna da rigakafin cutar kansa, a yau ya sanar da cewa an kunna maganin T cell, KROS 201, ya sami amincewar FDA don ci gaba da gwajin asibiti na Phase 1 a cikin marasa lafiya tare da maimaitawa. glioblastoma, nau'in ciwon daji na kwakwalwa. Kairos Pharma ne ke daukar nauyin gwajin lokaci na kuma za a gudanar da shi a Cedars Sinai Medical Center a Los Angeles.

Kairos Shugaba John Yu, MD yayi sharhi, "Wannan karbuwar IND ita ce ta biyu mafi mahimmancin ci gaba na asibiti a cikin watan da ya gabata yayin da Kairos ya hanzarta zuwa burinsa na asibiti don 2022. Wannan gwaji na asibiti na Farko na farko zai kunna ƙwayoyin T a kan tushen ciwon daji. Kwayoyin a tushen glioblastoma."

Kairos Babban Jami’in Kimiyya Neil Bhowmick, Ph.D. ya kara da cewa, "Wannan nasarar tana tura ambulan magungunan rigakafin da aka tsara don kai hari ga ƙwayoyin T daga cututtukan daji masu lalata."

KROS 201 da aka kunna T Kwayoyin (ATCs) sune masu kisa T waɗanda aka haɓaka a cikin al'adar tantanin halitta ta hanyar kunna fararen jini na aa tare da cytokines ko T cell masu kunna sigina kuma ta hanyar ƙaddamar da ƙwayoyin dendritic da aka ɗora tare da glioblastoma ciwon daji na musamman antigens. Kwayoyin T masu ƙarfi da aka kunna ana shigar dasu ta cikin jijiya cikin marasa lafiya tare da maimaita glioblastoma. An nuna waɗannan ƙwayoyin suna kashe ƙwayoyin cutar kansa, tushen tushen ciwon daji.

Bugu da ƙari ga gwaji na Phase 1 mai zuwa na farfadowa na T cell da aka kunna don KROS 201, an ba da gwajin lokaci na 2 na ENV105 tare da apalutamide kwanan nan FDA ta ba da IND a watan Fabrairu. An shirya gwajin mataki na 1 na ENV105 tare da Tagrisso (AstraZeneca) don ciwon huhu a cikin 2022.

Tare da wannan ci gaban ci gaban sa na asibiti, Kairos Pharma ya ba da sanarwar ba da izini na Ofishin Samfura da Alamar Kasuwanci ta Amurka na Abubuwan Haɓakawa da Hanyoyi don Magance Fibrosis. Wannan takardar shaidar ya ƙunshi hanyar magance fibrosis da wasu nau'o'in ciwon daji, abubuwan da ke tattare da kwayoyin halitta, da kuma gudanar da magani ta amfani da KROS-401, mai hana peptide cyclic na IL-4 da IL-13 cytokine receptor complex. An nuna wannan maganin warkewa don magance fibrosis da ciwon daji ta hanyar juyar da M1 zuwa M2 immunosuppressive macrophage a cikin duka ciwon daji da fibrosis.

Dr. John Yu, Shugaba na Kairos Pharma ya bayyana cewa, "Wannan ci gaban yana kara tallafawa tarin tarin kayan fasaha na Kairos kuma yana ba da damar ci gaban asibiti mara iyaka na wannan labari da kuma hanyoyin warkewa."

Kairos VP na Bincike da Ci gaba Dr. Ramachandran Murali, wanda ya kirkiri kwayoyin KROS 401, yayi sharhi, "KROS-401, ban da fibrosis da ciwon daji, yana buɗe sabon hanyar ci gaban warkewa don cututtukan jijiya kamar cutar Alzheimer." 

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...